Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis - Report - MDSpire

Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis

  • By

  • Zahra Moradi

  • Samaneh Toutounchian

  • Zahra Eghbali

  • Mahsa Barzegar

  • Dorsa Mohammadi

  • Dorsa Salabat

  • Niloofar Moradi

  • Maryam Barkhordar

  • Zahra Salehi

  • November 19, 2025

  • 0 min

Share

Clinical Report: Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients

Overview

This systematic review and meta-analysis evaluates the incidence of hypothyroidism in patients with hematological malignancies (HMs) compared to healthy individuals. It identifies significant risk factors contributing to hypothyroidism, including treatment modalities and patient demographics.

Background

Hematological malignancies represent a significant portion of cancer cases and are associated with various long-term complications, including endocrine disorders like hypothyroidism. Understanding the prevalence and risk factors for hypothyroidism in this population is crucial for improving patient management and outcomes. This study aims to clarify the incidence of hypothyroidism in HM patients and the factors influencing its development.

Data Highlights

Replace with a statement about the lack of specific numerical data or summarize key findings with available statistics.

Key Findings

  • Patients with hematological malignancies have a higher incidence of hypothyroidism compared to healthy individuals.
  • Risk factors for hypothyroidism include the type of malignancy and gender.
  • Treatment modalities such as radiation therapy and chemotherapy significantly increase the risk of developing hypothyroidism.
  • Specific chemotherapy regimens, particularly those involving chemoradiation and total body irradiation, are associated with a higher incidence of hypothyroidism.
  • Long-term monitoring for thyroid dysfunction is recommended for patients with HMs due to the increased risk.

Clinical Implications

Healthcare providers should be vigilant in monitoring thyroid function in patients with hematological malignancies, especially those who have undergone specific treatments. Early identification and management of hypothyroidism can improve patient quality of life and clinical outcomes.

Conclusion

The findings underscore the importance of routine thyroid function assessment in patients with hematological malignancies to mitigate the risk of hypothyroidism and its associated complications.

References

  1. Incidence and risk factors of hypothyroidism in patients with hematological malignancies compared to healthy population: a systematic review and meta-analysis - PMC
  2. Updates in Surgery — The Often Overlooked Influence of Hashimoto's Thyroiditis on Papillary Thyroid Carcinoma
  3. The Journal of Clinical Endocrinology & Metabolism — Association of Serum Thyrotropin Concentrations with Metabolic Disorders in the Elderly
  4. The Journal of Clinical Endocrinology & Metabolism — Thyroid Activity and Overall Mortality in Relation to Multimorbidity: Findings from Two Population-Based Studies
  5. The Association of Papillary Thyroid Carcinoma and Hashimoto's Thyroiditis
  6. Incidence and risk factors of hypothyroidism in patients with hematological malignancies compared to healthy population: a systematic review and meta-analysis - PMC
  7. Determining the Occurrence of Hypothyroidism Following Treatment With Radiation Therapy in Head and Neck Carcinoma Patients and the Associated Role of Risk Factors and Dose-Volume Histograms: A Prospective Study - PMC

Original Source(s)

Related Content